Medical Science Liaison - Remote / Telecommute

A Rare Opportunity to Shape the Future of Genomics Join a team of brilliant, passionate innovators determined to transform healthcare. Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments. If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong. We are looking for a field-based professional Medical Science Liaison (MSL) in Illinois, Minnesota, Missouri, Kansas, Florida, North Carolina, South Carolina, or Texas with scientific and clinical expertise in the space of prenatal genetic testing. The Medical Science Liaison (MSL) is responsible for providing medical and scientific support for BillionToOne's marketed products UNITY™ Complete. The Medical Science Liaison (MSL) is a remote position. Travel Requirements: Ideal candidate will have the ability to travel up to 70% nationwide Serve as a key liaison to health care providers (HCPs) Serve as a key member of the BillionToOne Medical Affairs team Develop relationships by engaging in scientific exchange with medical and scientific partners Support commercial team by providing impactful information that enhances the value and proper use of BillionToOne products Respond to HCP customer inquiries to provide focused and balanced clinical and scientific information that supports the appropriate use of BillionToOne’s prenatal products Adhere to internal standard processes and comply with regulatory and compliance requirements Master’s degree in Genetic Counseling

• 3-5 years of prenatal clinical and/or industry experience in related field required
• Expertise in discussing scientific content and context to multiple audiences
• Ability to travel (up to 70%) – percentage varies with geography

Bilingual in English and Spanish is a plus, but not required Working alongside brilliant, kind, passionate and dedicated colleagues, in an empowering environment, toward a global vision, striving for a future in which transformative molecular diagnostics can help millions of patients Multiple medical benefit options; Retirement savings program including a 4% Company match Latest and greatest hardware (laptop, lab equipment, facilities) At BillionToOne, we are proud to offer a combination of (1) competitive base pay, (2) generous equity options offering, (3) corporate bonus program, on top of (4) industry leading company benefits (free healthcare options, 401k match, very generous fully paid parental leave, etc.). This position is eligible for an annual bonus and receives a new hire equity grant of up to $30,000 at grant value, vesting over four years, plus annual equity refresh grants equal in value to the new hire grant. Together, the total four-year value of base, target bonus, and equity is up to approximately $793,000. We also offer competitive medical and dental coverage and a 401(k) with company match. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide. Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Unity Confirm™ enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne’s Fetal Cell Capture™ Technology. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest. Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics.